HC Wainwright & Co. Maintains Buy on Vera Therapeutics, Lowers Price Target to $90
Vera Therapeutics, Inc. Class A
Vera Therapeutics, Inc. Class A VERA | 0.00 |
HC Wainwright & Co. analyst Arthur He maintains Vera Therapeutics (NASDAQ:
VERA) with a Buy and lowers the price target from $125 to $90.
